About LA CaTS


Tulane plays lead role in major diabetes drug trial

Released: Friday, June 17, 2016
Keith Brannon kbrannon@tulane.edu

When American Diabetes Association officials gathered in New Orleans earlier this week and announced results of a major international drug trial, most of the focus was on the finding that the glucose-lowering drug Liraglutide reduces cardiovascular events by 13 percent for high-risk type 2 diabetes patients.

The trial, called Liraglutide Effect and Action in Diabetes - Evaluation of Cardiovascular Outcome Results (LEADER), hit a benchmark that didn’t make headlines, but astonished the research community. It showed a phenomenally high patient follow-up rate of 99.7 percent despite spanning five years, 410 sites in 32 countries and involving 9,340 patients.

Roberta McDuffie, director of clinical research for Tulane University Clinical Translational Unit, played a vital role in making that happen. McDuffie was the national study coordinator for all 118 sites in the United States and a member of the study’s International Panel for Recruitment and Retention. McDuffie worked directly with staff at all domestic sites to make sure everything possible was being done to reach patients who weren’t responding to check in.

“This is a new record for the smallest number of loss-to-follow-up ratio for a cardiovascular outcomes trial of this size. It’s particularly notable because the FDA puts such a value on this for the validity of your data in the study results,” McDuffie said. “When they announced that retention rate, people were amazed. People stood up and were clapping.”

Tulane was also one of the largest sites for the LEADER trial with about 60 participants. Dr. Tina Theti was the local investigator and Dr. Vivian Fonseca, Tullis-Tulane Alumni Chair in Diabetes and professor of medicine, played a lead role in designing the study.

“Tulane was very involved with this trial,” said Fonseca, who spent eight years on the LEADER global expert panel (from the study’s inception to completion) and chaired the U.S. national expert panel.

Most of the work was handled in Tulane’s Clinical Translational Unit, a suite of clinical rooms in the Tidewater Building that was expanded several years ago thanks to funding from the Louisiana Clinical and Translational Science (LA CaTS) Center.


About the Louisiana Clinical and Translational Science (LA CaTS) Center
The LA CaTS Center is comprised of three primary collaborating institutions in the state, including LSU's Pennington Biomedical Research Center in Baton Rouge, LSU Health Sciences Center in New Orleans, and Tulane University School of Medicine in New Orleans – and also includes six research partners: LSU Health Sciences Center in Shreveport, Louisiana State University in Baton Rouge, and in New Orleans, Xavier University of Louisiana, Children’s Hospital, Ochsner Health System, Southeast Louisiana Veterans Health Care System, and University Medical Center.  The LA CaTS Center’s vision for Louisiana encompasses the strengths and capacities unique to each member institution and represents a unified, comprehensive approach for targeting prevention, care and research of chronic diseases in the underserved population.  The scholar program is supported in part by U54 GM104940 from the National Institute of General Medical Sciences of the National Institutes of Health which funds the Louisiana Clinical and Translational Science Center.  For more information, please visit www.lacats.org.